Public record
Victoza: the public record
Each table is computed from the named federal dataset as of its data date; the method is under each one.
Medicaid
Medicaid prescriptions for Victoza by state
State Medicaid programmes paid for 50,536 Victoza prescriptions in 2025, with $31.9M reimbursed before rebates. Ohio reported the most (6,622), followed by Georgia (4,047) and California (3,862); 41 states and territories reported any.
| Measure | Value | Note |
|---|---|---|
| Prescriptions paid by Medicaid, 2025 | 50,536 | |
| Total reimbursed before rebates, 2025 | $31.9M | |
| States and territories reporting | 41 | with at least one count CMS did not suppress |
| Ohio | 6,622 prescriptions | $4.1M reimbursed |
| Georgia | 4,047 prescriptions | $2.4M reimbursed |
| California | 3,862 prescriptions | $2.5M reimbursed |
| Arkansas | 3,861 prescriptions | $2.5M reimbursed |
| Virginia | 3,609 prescriptions | $2.2M reimbursed |
How this was calculated
Matched each Medicaid product code to the FDA NDC Directory by labeler and product code, kept finished single-ingredient products, then summed prescriptions and reimbursement by state. National roll-up and suppressed rows dropped.
Victoza only (brand-name liraglutide), fee-for-service and managed care, 2025
Counts under 11 are suppressed by CMS and left out, so totals are a floor. Amounts are before rebates. Differences between states reflect programme size and coverage rules. Compounded products are not included.
Pharmacy cost
Pharmacy acquisition cost (NADAC) for Victoza
Retail pharmacies paid an average of $87.76 per mL for VICTOZA 2-PAK 18 MG/3 ML PEN as of 2026-11-11, compared with $87.64 twelve months earlier (+0.1%). This is a pharmacy purchase cost, not a patient price.
| Measure | Value | Note |
|---|---|---|
| VICTOZA 2-PAK 18 MG/3 ML PEN, now | $87.76 per mL | |
| VICTOZA 2-PAK 18 MG/3 ML PEN, 12 months earlier | $87.64 per mL | |
| Change over 12 months | +0.1% | |
| VICTOZA 3-PAK 18 MG/3 ML PEN | $87.75 per mL | 12 months earlier $87.55 (+0.2%) |
How this was calculated
Matched NADAC product codes to the FDA NDC Directory, kept finished single-ingredient products, and listed the product descriptions with the most package codes. The earlier price is the same package code in the file one year before.
Victoza (brand-name liraglutide) in the weekly NADAC file of 2026-11-11, compared with the file of 2025-11-12
NADAC is the average invoice price retail pharmacies pay, from a voluntary survey. It leaves out rebates, dispensing fees and markups, and it is not what a patient or insurer pays. Compounded products are not surveyed.